Vir Biotechnology, Inc. disclosure: SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M1) L.P. and SVF Endurance (Cayman) Limited report shared beneficial ownership of 10,948,093 shares of Common Stock as of March 31, 2026, representing 6.5% of the class. The statement notes 168,651,974 shares outstanding as of April 29, 2026. SVF Endurance (Cayman) Limited is the record holder, SVF is its sole owner, and SBIA UK serves as SVF's appointed AIFM and may be deemed to share beneficial ownership.
Positive
None.
Negative
None.
Insights
Large passive stake disclosed: 10,948,093 shares (6.5%).
The disclosure lists a shared beneficial position of 10,948,093 shares held through related entities, reported as of March 31, 2026. The filing ties this position to an outstanding base of 168,651,974 shares as of April 29, 2026.
Holder structure shows the record holder and upstream owner relationships; cash‑flow treatment of any transactions and future trading intentions are not stated in the excerpt.
Disclosure clarifies voting/dispositive powers and entity roles.
The reporting persons state 0 sole voting and 10,948,093 shared voting and dispositive power, with SBIA UK identified as AIFM for SVF. This attributes decision authority to the manager in accordance with the Alternative Investment Fund Managers Directive.
Governance implications rest on shared control; subsequent filings would be required to show any changes in holdings or voting arrangements.
Key Figures
Shares beneficially owned:10,948,093 sharesPercent of class:6.5%Shares outstanding:168,651,974 shares
3 metrics
Shares beneficially owned10,948,093 sharesBeneficial ownership as of <date>March 31, 2026</date>
Percent of class<percent>6.5%</percent>Calculated using outstanding shares figure disclosed by issuer
Shares outstanding168,651,974 sharesOutstanding as of <date>April 29, 2026</date>
"The ownership information presented herein represents beneficial ownership of Common Stock"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive powerregulatory
"Shared Dispositive Power 10,948,093.00"
AIFMfinancial
"SBIA UK has been appointed as alternative investment fund manager ("AIFM")"
An AIFM is a regulated manager that runs alternative investment funds—vehicles like hedge funds, private equity, or real estate funds—under specific rules designed to protect investors. Think of an AIFM as the licensed driver of a bus carrying other people’s money: it must follow safety rules, report performance and risks, and hold controls that make the fund’s behavior more transparent and accountable to investors.
Schedule 13G/Aregulatory
"(Amendment No. 4 ) Vir Biotechnology, Inc. Common Stock"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
What stake does SB Investment Advisers (UK) report in VIR?
SB Investment Advisers (UK) reports shared beneficial ownership of 10,948,093 shares (6.5%). This stake is reported as of March 31, 2026 and is shown through affiliated entities in the filing.
Who is the record holder for the reported VIR shares?
The filing identifies SVF Endurance (Cayman) Limited as the record holder of the 10,948,093 shares. SVF is identified as the sole owner of that record-holder in the disclosure.
What basis is used to calculate the 6.5% ownership in VIR?
The 6.5% figure is calculated using 168,651,974 shares outstanding as of April 29, 2026, per the issuer's referenced quarterly report, tied to beneficial ownership as of March 31, 2026.
Does SBIA UK have sole voting control over the VIR shares?
No. The filing reports 0 sole voting power and 10,948,093 shared voting power, indicating voting and dispositive authority are reported as shared among the named reporting persons.
Are trading intentions or transactions disclosed in this Schedule 13G/A for VIR?
The filing provides beneficial ownership and power allocation only. It does not disclose trading intentions, planned sales, or purchases in the excerpt provided.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
Vir Biotechnology, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value
(Title of Class of Securities)
92764N102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
92764N102
1
Names of Reporting Persons
SB Investment Advisers (UK) Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,948,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,948,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,948,093.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
92764N102
1
Names of Reporting Persons
SoftBank Vision Fund (AIV M1) L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,948,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,948,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,948,093.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
92764N102
1
Names of Reporting Persons
SVF Endurance (Cayman) Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
10,948,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
10,948,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
10,948,093.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Vir Biotechnology, Inc.
(b)
Address of issuer's principal executive offices:
1800 Owens Street, Suite 900, San Francisco, CA 94158
Item 2.
(a)
Name of person filing:
Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:
SB Investment Advisers (UK) Limited ("SBIA UK")
SoftBank Vision Fund (AIV M1) L.P. ("SVF")
SVF Endurance (Cayman) Limited
(b)
Address or principal business office or, if none, residence:
The principal business address for each of SBIA UK is 69 Grosvenor Street, Mayfair, London W1K 3JP, England, United Kingdom. The principal business address of SVF is 1521 Concord Pike, Wilmington, DE 19803. The principal business address of SVF Endurance (Cayman) Limited is c/o Walkers Corporate Ltd., 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.
(c)
Citizenship:
SBIA UK is organized under the laws of England and Wales. SVF is organized under the laws of the State of Delaware. SVF Endurance (Cayman) Limited is organized under the laws of the Cayman Islands.
(d)
Title of class of securities:
Common Stock, $0.0001 par value
(e)
CUSIP No.:
92764N102
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of March 31, 2026, based upon 168,651,974 shares of Common Stock outstanding as of April 29, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.
SVF Endurance (Cayman) Limited is the record holder of the securities reported herein.
SVF is the sole owner of SVF Endurance (Cayman) Limited. SBIA UK has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. As a result of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the securities reported herein.
(b)
Percent of class:
6.5%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
10,948,093
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
10,948,093
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
